-
721
The application of a novel hydrodynamic cavitation device to debride intra-articular monosodium urate crystals
Published 2023-02-01Subjects: “…Gout…”
Get full text
Article -
722
-
723
Anti-Hyperuricemic Effects of Oenanthe javanica Extracts in Hyperuricemia-Induced Rats
Published 2023-02-01Subjects:Article -
724
-
725
Yellow Dyes of Historical Importance: A Handful of Weld Yellows from the 18th-Century Recipe Books of French Master Dyers Antoine Janot and Paul Gout
Published 2023-11-01“…Antoine Janot and Paul Gout were 18th-century master dyers who specialised in the piece-dyeing of fine wool broadcloths manufactured in Languedoc (southern France) for exportation to the Levant. …”
Get full text
Article -
726
-
727
Risk of a major adverse cardiovascular event (MACE) following first-ever hospitalisation for acute gout: a Western Australian population-level linked data study.
Published 2022-08-01Subjects: “…acute gout…”
Get full text
Article -
728
-
729
-
730
Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)
Published 2023-04-01Subjects: “…Gout…”
Get full text
Article -
731
-
732
-
733
-
734
-
735
-
736
-
737
-
738
-
739
A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
Published 2023-08-01“…Objective To assess 12‐month safety and efficacy of pegloticase + methotrexate (MTX) versus pegloticase + placebo (PBO) cotherapy in a PBO‐controlled, double‐blind trial (A randomized, double‐blind, placebo‐controlled, multicenter, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase [MIRROR RCT]). Methods Patients with uncontrolled gout (serum urate level [SU] ≥7 mg/dl, oral urate‐lowering therapy failure or intolerance, and presence of one or more gout symptoms [one or more tophi, two or more flares in 12 months, gouty arthropathy]) were randomized 2:1 to receive pegloticase (8‐mg infusion every 2 weeks) with blinded MTX (oral 15 mg/week) or PBO for 52 weeks. …”
Get full text
Article -
740
Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial
Published 2023-01-01Subjects: “…Gout…”
Get full text
Article